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Abstract 
Purpose: To investigate the antibiotic resistance pattern of uropathogenic Escherichia coli (UPEC) 
strains isolated from pregnant women with history of recurrent urinary tract infections (RUTIs) and 
healthy pregnant women.  
Methods: A total of 485 high vaginal swab specimens were collected from pregnant women with history 
of RUTIs and healthy ones. Samples were cultured and those that were E. coli positive were analyzed 
by polymerase chain reaction (PCR) and disk diffusion tests.  
Results: Twenty eight out of 445 (6.29 %) samples were positive for E. coli. Prevalence of E. coli in 
pregnant women with history of RUTIs and healthy ones were 9 and 4.08 %, respectively. Women older 
than 40 years were the most commonly infected. UPEC strains showed the highest levels of resistance 
against ampicillin (96.42 %), tetracycline (85.71 %), amikacin (71.42 %), ciprofloxacin (67.85 %) and 
gentamycin (58.71 %).  
Conclusion: RUTIs and pregnancy in old age are two important risk factors for transmission of UPEC 
strains from the urinary tract into the vagina. Primary treatment of infected pregnant women with 
imipenem, mezlocillin and nitrofurantoin would be effective for the prevention and management of 
vaginal infections in pregnant women. 
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Pregnancy causes numerous changes in the 
woman’s body. During pregnancy, the level of 
body immune system is reduced. Hormonal and 
mechanical changes increase the risk of urinary 
stasis and vesicoureteral reflux. These changes, 
along with an already short urethra and difficulty 
with hygiene due to a distended pregnant belly, 
increase the frequency of urinary tract infections 
(UTIs) in pregnant women [1]. Indeed, UTIs are 
among the most common bacterial infections 
during pregnancy [1]. Urinary tract infections 
(UTIs) are among the most common bacterial 
infections diseases in human [2-4]. UTIs account 
for more than 8 million referrals to hospitals, 1.5 
million hospitalization, and 300,000 severe 
clinical syndromes in the United States annually 
[2,5]. UTIs is an important cause of mortality and 
morbidity [6,7]. 
 
Uropathogenic Escherichia coli (UPEC) strains 
are the most prevalent causes of UTIs around 
the world [3,8]. Based on the hypothesis, UPEC 
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strains can transfer from the urinary tract of 
pregnant women who have low levels of 
immunity into the reproductive system [9,10]. 
This maybe more common in pregnant women 
with history of recurrent UTIs (EUTIs). 
Association of bacterial vaginosis and UTIs in 
pregnant women have also been reported 
previously [10-12]. 
 
In an overview, treatment of the cases of UTIs 
and vaginal infections were carried out by 
antibiotic therapy, but high prevalence of 
antibiotic resistance in the UPEC strains of 
clinical infections, with the attenelant prolonged 
severe diseases, [3,13,14]. According to recent 
epidemiological studies, UPEC strains showed a 
high prevalence of resistance (50-100 %) against 
commonly used antibiotics, including tetracycline, 
cefotaxime, gentamycin, ampicillin, amikacin, 
ciprofloxacin (5 µg/disk), cotrimoxazole, 
norfloxacin and cephalothin [3,13,14]. with to the 
mutable status of the antibiotic resistance in 
UPEC strains of clinical samples in cases of 
pregnant women which are of high clinical 
importance, the distribution of antibiotic 
resistance pattern should be evaluated.  
 
Due to the uncertain status of UPEC strains in 
pregnant women, the present study was carried 
out to investigate antibiotic resistance pattern of 
the UPEC strains isolated from pregnant women 






This work was approved by the ethical committee 
of Department of Infectious Diseases, College of 
Medicine, AJA University of Medical Sciences, 
Tehran, Iran (ref no. 20275 MD). Written 
informed consent was obtained from the patients 
or a close relative. All stages of sampling were 
done in such a way as to minimize pain and 
harm to the patients and international guidelines 
for human studies were followed [15]. 
 
Study population and samples collection 
 
Total of 240 high vaginal swab specimens were 
collected from pregnant women with history of 
RUTIs from March to December 2015. Besides, 
245 high vaginal swabs were also taken from 
healthy pregnant women who were referred to 
the Obstetrics and Gynecology Centers, Iran for 
routine pregnancy checks. Specimens were 
collected from the ventral fornix without any 
contact with urine and external parts of 
reproductive system, using speculum and 
commercial sterile cotton-tipped swabs. All 
specimens were collected by an expert midwife. 
 
Escherichia coli identification 
 
All samples were transferred to the laboratory in 
a cooler with ice packs. A, 3 mL of each 
specimen was blended with 225 mL of Lactose 
Broth (LB, Merck, Germany) for 2 min at normal 
speed, using a Stomacher lab blender and 
incubated at 37 °C for 24 h. One milliliter sample 
of the nutrient broth culture was mixed with 9 mL 
of MacConkey broth (MC broth, Merck, 
Germany) and further incubated at 37 °C for 24 
h. One loop of each tube was streaked on 
MacConkey agar (MC agar, Merck, Germany). A 
typical colony of E. coli was streaked on Eosin 
Methylene Blue agar (EMB agar, Merck, 
Germany) plates and incubated at 37 °C for 24 h. 
A green metallic colonies from each plate with 
typical E. coli morphology was selected and 
examined by biochemical tests, including 
hydrogen sulfide, citrate, urease, methyl red 
(MR), Voges–Proskauer (VP), Triple sugar iron 
agar (TSI agar) and indole. 
 
PCR confirmation of Escherichia coli strains 
 
Total genomic DNA was extracted from the 
bacterial colonies using the DNA purification kit 
(Fermentas, Germany) according to the 
instructions. The colonies were confirmed using 
PCR method [16]. The 10 ml bacterial DNA 
extract and controls were amplified with 0.5 mM 
primers (Forward: 5’-AGTTTGATCCTGGCTCAG 
-3’ and Reverse: 5’-AGGCCCGGGAACGTATT 
CAC-3’) (1343 bp), 200 mM of each dNTP 
(Fermentas, Germany), 2 mM MgCl2, 10 mM KCl 
PCR buffer and 1.0 U Taq polymerase 
(Fermentas, Germany). The DNA was amplified 
in a programmable thermal cycler (Eppendorf, 
Mastercycler® 5330, Eppendorf-Netheler-Hinz 
GmbH, Hamburg, Germany) PCR device using 
the following protocol: 94 ºC for 5 min, 40 cycles 
of 94 ºC for 1 min, 55 ºC for 1 min, 72 ºC for 2 
min, and final 72 ºC for 5 min. Amplified products 
were stained with SYBR DNA gel stain, 
separated electrophoretically in 1.5 % agarose 
gels, and imaged using an UV transilluminator 
and digital capture system. E. coli ATCC 8739 
and sterile distilled water were used as a positive 
and negative controls, respectively.  
 
Antimicrobial susceptibility testing 
 
Antimicrobial resistance pattern was performed 
by the Kirby–Bauer disc diffusion method using 
Mueller–Hinton agar (HiMedia Laboratories, 
Mumbai, India, MV1084), according to the 
Clinical and Laboratory Standards Institute 
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(CLSI) guidelines [17]. After incubating the 
inoculated plate aerobically at 37 °C for 18 - 24 h 
in an aerobic atmosphere, the susceptibility of 
the E. coli isolates against tetracycline (30 
µg/disk), cefotaxime (30 µg/disk), gentamycin (10 
µg/disk), ampicillin (10 µ/disk), amikacin (30 
µ/disk), imipenem (30 µ/disk), mezlocillin (30 
µ/disk), ciprofloxacin (5 µg/disk), cotrimoxazole 
(30 µg/disk), norfloxacin (30 µg/disk), ofloxacin (5 
µg/disk), nitrofurantoin (300 µg/disk), nalidixic 
acid (30 µg/disk), cephalothin (30 µg/disk) and 
clindamycin (2 µg/disk) antimicrobial agents was 
measured. Results were interpreted in 
accordance with interpretative criteria provided 
by CLSI (2012). E. coli ATCC 8739 was used as 
quality control organisms in antimicrobial 
susceptibility determination. 
 
Statistical analysis  
 
The data were analyzed using SPSS software 
(version 17, SPSS Inc, United States) using Chi-
square and Fisher exact tests to find any 
significant correlation between incidence of E. 
coli strains and their antibiotic resistance 
properties in pregnant women. Differences were 




Table 1 shows the total prevalence of E. coli in 
pregnant women with RUTIs and healthy 
pregnant women. All of the E. coli isolates were 
authenticated by the PCR amplification. Figure 1 
represents the results of gel electrophoresis for 
E. coli bacterium. We found that 28 out of 445 
(6.29 %) swab samples were positive for E. coli.  
On the other hand, 18 out of 200 (9 %) swab 
samples from pregnant women with history of 
RUTIs, while 10 out of 245 (4.08 %) swab 
samples from healthy pregnant women were 
positive for E. coli. Pregnant women older than 
40 years had the highest prevalence of E. coli 
(12.71 %). Statistical significant differences were 
seen between the types of samples and 
prevalence of E. coli (p < 0.01) and between the 
age of women and prevalence of E. coli (p < 
0.05). 
 
Table 2 indicates the antimicrobial resistance 
pattern of E. coli strains isolated from pregnant 
women with RUTIs and healthy pregnant women. 
E. coli strains from our investigation harbored the 
highest levels of resistance against ampicillin 
(96.42 %), tetracycline (85.71 %), amikacin 
(71.42 %), ciprofloxacin (67.85 %) and 
gentamycin (58.71 %) antibiotic agents. Levels of 
antibiotic resistances in pregnant women with 
history of RUTIs were higher than those of 
healthy pregnant women (p < 0.05).  The most 
effective antibiotic agents against E. coli strains 
from the high vaginal swab samples of pregnant 
women were imipenem (3.57 %), mezlocillin (25 




The results of present study are the first 
prevalence report of the UPEC strains and their 
antibiotic resistance pattern in the swab samples 
taken directly from the high vaginal swab 
samples of pregnant women. Probably the 
pregnant women of our study had vaginitis due to 
the presence of UPEC strains. History of RUTIs 
can accentuate the above hypothesis. It is 
commonly accepted that a high frequency of UTI 
during pregnancy would be due to physiological 
changes the human body undergoes during 
pregnancy. Bacterial vaginosis has been 
reported as the most common vaginal infection. 
Its prevalence varies from 10 to 65 % [10]. Many 
serious obstetric and gynecological 
complications have been associated with 
bacterial vaginosis. Such obstetric complications 
included premature rupture of membranes, 
preterm labor and delivery, endometritis and 
chorioamnionitis [18]. 
 
Table 1: Prevalence of Escherichia coli in pregnant women with RUTIs and healthy ones 
 
Sample No. samples collected Escherichia coli-positive (%) 
Pregnant women 
with history of 
RUTIs 
<20 years 70 3 (4.28) 
20-40 years 80 6 (7.5) 
>40 years 50 9 (18) 
Total 200 18 (9) 
Healthy pregnant 
women 
<20 years 82 1 (1.21) 
20-40 years 95 3 (3.15) 
>40 years 68 6 (8.82) 
Total 245 10 (4.08) 
Total 
<20 years 152 4 (2.63) 
20-40 years 175 9 (5.14) 
>40 years 118 15 (12.71) 
Total 445 28 (6.29) 
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Type of samples (no. positive) 
Pregnant women 






Tetracycline 17 (94.44) 7 (70) 24 (85.71) 
Cefotaxime 8 (44.44) 2 (20) 10 (35.71) 
Gentamycin 17 (94.44) 7 (70) 24 (58.71) 
Ampicillin 18 (100) 9 (90) 27 (96.42) 
Amikacin 15 (83.33) 5 (50) 20 (71.42) 
Imipenem 1 (5.55) - 1 (3.57) 
Mezlocillin 5 (27.77) 2 (20) 7 (25) 
Ciprofloxacin 14 (77.77) 5 (50) 19 (67.85) 
Cotrimoxazole 7 (38.88) 3 (30) 10 (35.71) 
Norfloxacin 8 (44.44) 2 (20) 10 (35.71) 
Ofloxacin 7 (38.88) 2 (20) 9 (32.14) 
Nitrofurantoin 6 (33.33) 1 (10) 7 (25) 
Nalidixic acid 7 (38.88) 1 (10) 8 (28.57) 
Cephalothin 9 (50) 3 (30) 12 (42.85) 
Clindamycin 10 (55.55) 2 (20) 12 (42.85) 
 
We found that the prevalence of UPEC strains in 
the swab samples of pregnant women with 
history of RUTIs and in healthy pregnant women 
were 9 and 4.08 %, respectively. Transmission of 
pathogenic strains of E. coli from the urinary tract 
to the vagina could be the main factor for the 
higher prevalence of UPEC strains in the high 
vaginal swab samples of pregnant women with 
history of RUTIs. The observed prevalence of 
UPEC strains in the high vaginal swab samples 
of healthy pregnant women could also be due to 
the fact that they may have been infected with 
UTIs in the past or even vaginitis which may 
been forgotten or become asymptomatic. The 
results of our investigation revealed that 
pregnancy in older ages could be the main risk 
factors in the transmission of infections from 
urinary into the reproductive system.  
 
Our study also focused on the antibiotic 
resistance pattern of UPEC strains isolated from 
pregnant women. As a result of high and 
irregular prescription of antibiotic coupled with 
high levels of UPEC resistance against 
commonly used antibiotics, it was not surprising 
that most of the UPEC strains of our study were 
resistant against ampicillin, tetracycline, 
amikacin, ciprofloxacin, gentamycin, 
cotrimoxazole, norfloxacin, ofloxacin, 
nitrofurantoin, cephalothin and clindamycin. This 
observation has been corroborated by some 
literature reports. Barati et al [19] revealed that 
urine samples of pregnant women were 
contaminated with E. coli strains. They showed 
that the sensitivity of E. coli isolates against 
antibiotics were coamoxiclav (5.72 %), ampicillin 
(8.86 %), amoxicillin (11.87 %), cefazolin (32.12 
%), cephalexin (36.1 %), gentamicin (40.28 %), 
cotrimoxazole (48.15 %), nalidixic acid (55.3 %), 
nitrofurantoin (72.48 %) and ceftriaxone (80.78 
%) which was similar to our results. Prevalence 
of UPEC strains in pregnant women in Sweden, 
Uganda and Vietnam during first, second and 
third trimester of pregnancy were 22, 36 and 42; 
9, 68 and 23 % and finally 12, 40 and 48 %, 
respectively [20]. Guiral et al [21] in a study 
which was conducted on prevalence of E. coli in 
the genital tracts of the pregnant women, 
reported 86 out of 648 samples (13 %) which 
was higher than our results. High prevalence of 
UPEC strains in the vaginal samples of pregnant 
women have also been reported previously [22-
24]. Prevalence of antibiotic resistance in the E. 
coli strains isolated from pregnant women of 
Tanzania against ampicillin, sulfamethazole-
trimethoprim, tetracycline, nitrofurantoin, 
ceftriaxone, gentamycin, ciprofloxacin and 
imipenem were 52.9, 64.7, 58.8, 5.9, 29.4, 5.9, 
11.8 and 0 %, respectively [25]. Similar results 
have been reported from Nigeria [25], Iraq [27] 




As far as we know, the present study is the first 
prevalence report on antibiotic resistance pattern 
of UPEC strains in pregnant women with history 
of RUTIs. The findings indicate that RUTIs and 
pregnancy in old age may be the two most 
important risk factors for the transmission of 
UPEC strains from the urinary tract to the vagina. 
Due to the clinical importance of the presence of 
resistant UPEC strains in upper part of the 
vaginal of pregnant women, accurate 
identification of these women and their primary 
treatment with imipenem, mezlocillin and 
nitrofurantoin may be effective in the 
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management and prevention of reproductive 
complications. Further studies are required to 
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